Compare · ABT vs MURA
ABT vs MURA
Side-by-side comparison of Abbott Laboratories (ABT) and Mural Oncology plc (MURA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MURA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $163.47B.
- Over the past year, ABT is down 28.1% and MURA is down 22.5% - MURA leads by 5.6 points.
- ABT has hit the wire 24 times in the past 4 weeks while MURA has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 4 for MURA).
- Company
- Abbott Laboratories
- Mural Oncology plc
- Price
- $93.86+1.12%
- $2.03-0.49%
- Market cap
- $163.47B
- -
- 1M return
- -9.75%
- -2.87%
- 1Y return
- -28.09%
- -22.52%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 24
- 0
- Recent ratings
- 25
- 4
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
- Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)
- Director Roman Michael F was granted 2,286 units of Common shares without par value, increasing direct ownership by 27% to 10,764 units (SEC Form 4)
- Director O'Grady Michael was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)
- Director Mckinstry Nancy was granted 2,286 units of Common shares without par value, increasing direct ownership by 6% to 41,010 units (SEC Form 4)
- Director Mcdew Darren W was granted 2,286 units of Common shares without par value, increasing direct ownership by 22% to 12,678 units (SEC Form 4)
- Director Kumbier Michelle was granted 2,286 units of Common shares without par value, increasing direct ownership by 15% to 18,000 units (SEC Form 4)
- Director Gonzalez Patricia Paola was granted 2,286 units of Common shares without par value, increasing direct ownership by 33% to 9,205 units (SEC Form 4)
Latest MURA
- Amendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plc
- SEC Form 15-12G filed by Mural Oncology plc
- SEC Form EFFECT filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form POS AM filed by Mural Oncology plc
- SEC Form 4 filed by Director Hickey Benjamin
- Chief Executive Officer Loew Caroline returned 293,059 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Cuss Francis M